Apyx Medical Q4 revenue beats on Surgical Aesthetics unit strength

Apyx Medical

10/03/2026 11:08

Overview

Surgical aesthetics firm's Q4 revenue rose 34.7% yr/yr, beating analyst expectations

Adjusted EBITDA for Q4 was positive, beating analyst estimates

Company scaling U.S. launch of AYON Body Contouring System amid strong demand

Outlook

Apyx Medical expects FY2026 total revenue between $57.5 mln and $58.5 mln

Company anticipates FY2026 Surgical Aesthetics revenue between $53 mln and $54 mln

Apyx Medical projects FY2026 OEM revenue to be approximately $4.5 mln

Result Drivers

AYON LAUNCH - Scaling U.S. commercial launch of AYON Body Contouring System to meet strong market demand

SURGICAL AESTHETICS GROWTH - Surgical Aesthetics revenue increased 38.1% in Q4 2025, driven by U.S. sales of AYON

OEM REVENUE INCREASE - OEM revenue rose 15.6% in Q4 2025, but future focus remains on Surgical Aesthetics

Company press release: ID:nGNX5wHZMQ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Beat
$19.16 mln
$18.40 mln (4 Analysts)
Q4 EPS
-$0.03
Q4 Net Income
-$1.24 mln
Q4 Adjusted EBITDA
Beat
$689,000
$3,000 (3 Analysts)
Q4 Gross Margin
62.60%
Q4 Income From Operations
$11,000
Q4 Pretax Profit
-$1.15 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Apyx Medical Inc is $5.50, about 60.3% above its March 9 closing price of $3.43

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)